Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Genes, Chromosomes & Cancer
|
September 4, 2008
The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1
Helen Parker, Qian An, Kerry Barber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome
Nicholas J Dickens, Brian A Walker, Paola E Leone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2011
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
Kevin D Boyd, Fiona M Ross, Brian A Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma
David C Johnson, Sophie L Corthals, Brian A Walker, et al.
British Journal of Haematology
|
May 10, 2005
Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study
Christine J Harrison, Anthony V Moorman, Kerry E Barber, et al.
Genes, Chromosomes & Cancer
|
October 1, 2011
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
Kevin D Boyd, Fiona M Ross, William J Tapper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implications
Paola E Leone, Brian A Walker, Matthew W Jenner, et al.
Nature Genetics
|
July 6, 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst, Andrew J Chase, Joannah Score, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
Andy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
Reply to M. Roschewski et al
Andy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Genes, Chromosomes & Cancer
|
September 4, 2008
The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1
Helen Parker, Qian An, Kerry Barber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome
Nicholas J Dickens, Brian A Walker, Paola E Leone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2011
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
Kevin D Boyd, Fiona M Ross, Brian A Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma
David C Johnson, Sophie L Corthals, Brian A Walker, et al.
British Journal of Haematology
|
May 10, 2005
Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study
Christine J Harrison, Anthony V Moorman, Kerry E Barber, et al.
Genes, Chromosomes & Cancer
|
October 1, 2011
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
Kevin D Boyd, Fiona M Ross, William J Tapper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implications
Paola E Leone, Brian A Walker, Matthew W Jenner, et al.
Nature Genetics
|
July 6, 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst, Andrew J Chase, Joannah Score, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
Andy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
Reply to M. Roschewski et al
Andy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Page
of 6